Bioventus receives FDA 510k clearances for two next-gen PNS products

Bioventus (BVS) announced a significant milestone with the U.S. Food and Drug Administration 510(k) clearances for both TalisMann and StimTrial, expanding the Company’s innovative portfolio of Peripheral Nerve Stimulation, PNS, solutions for chronic pain management. These two clearances mark an important step forward for Bioventus and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be growing above 20 percent annually and expected to exceed $500 million by 2029.